Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Precision Biosciences (DTIL) Equity Average (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Equity Average for 8 consecutive years, with $25.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Equity Average fell 63.69% to $25.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $25.3 million, a 63.69% decrease, with the full-year FY2024 number at $37.6 million, down 5.09% from a year prior.
  • Equity Average was $25.3 million for Q3 2025 at Precision Biosciences, down from $41.7 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $101.0 million in Q3 2021 to a low of $24.0 million in Q4 2023.
  • A 5-year average of $59.9 million and a median of $56.0 million in 2024 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: plummeted 66.91% in 2023, then soared 153.02% in 2024.
  • Precision Biosciences' Equity Average stood at $96.3 million in 2021, then decreased by 24.82% to $72.4 million in 2022, then tumbled by 66.91% to $24.0 million in 2023, then skyrocketed by 153.02% to $60.6 million in 2024, then plummeted by 58.2% to $25.3 million in 2025.
  • Per Business Quant, the three most recent readings for DTIL's Equity Average are $25.3 million (Q3 2025), $41.7 million (Q2 2025), and $52.9 million (Q1 2025).